These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

486 related articles for article (PubMed ID: 25060490)

  • 1. Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma.
    McDermott D; Lebbé C; Hodi FS; Maio M; Weber JS; Wolchok JD; Thompson JA; Balch CM
    Cancer Treat Rev; 2014 Oct; 40(9):1056-64. PubMed ID: 25060490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.
    Ott PA; Hodi FS; Robert C
    Clin Cancer Res; 2013 Oct; 19(19):5300-9. PubMed ID: 24089443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic use of anti-CTLA-4 antibodies.
    Blank CU; Enk A
    Int Immunol; 2015 Jan; 27(1):3-10. PubMed ID: 25038057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy of patients with metastatic melanoma.
    Yu Z; Si L
    Chin Clin Oncol; 2017 Apr; 6(2):20. PubMed ID: 28482673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy in melanoma: Recent advances and future directions.
    Franklin C; Livingstone E; Roesch A; Schilling B; Schadendorf D
    Eur J Surg Oncol; 2017 Mar; 43(3):604-611. PubMed ID: 27769635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The ipilimumab lesson in melanoma: achieving long-term survival.
    Delyon J; Maio M; Lebbé C
    Semin Oncol; 2015 Jun; 42(3):387-401. PubMed ID: 25965357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Advances in immunotherapy for metastatic melanoma].
    Oláh J
    Magy Onkol; 2017 Jun; 61(2):132-136. PubMed ID: 28585614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy for the management of advanced melanoma: the next steps.
    Zikich D; Schachter J; Besser MJ
    Am J Clin Dermatol; 2013 Aug; 14(4):261-72. PubMed ID: 23516145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted agents and immunotherapies: optimizing outcomes in melanoma.
    Luke JJ; Flaherty KT; Ribas A; Long GV
    Nat Rev Clin Oncol; 2017 Aug; 14(8):463-482. PubMed ID: 28374786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relevance of serum biomarkers associated with melanoma during follow-up of anti-CTLA-4 immunotherapy.
    Felix J; Cassinat B; Porcher R; Schlageter MH; Maubec E; Pages C; Baroudjian B; Homyrda L; Boukouaci W; Tamouza R; Bagot M; Caignard A; Toubert A; Lebbé C; Moins-Teisserenc H
    Int Immunopharmacol; 2016 Nov; 40():466-473. PubMed ID: 27728898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ipilimumab in advanced melanoma: reports of long-lasting responses.
    Farolfi A; Ridolfi L; Guidoboni M; Nicoletti SV; Piciucchi S; Valmorri L; Costantini M; Scarpi E; Amadori D; Ridolfi R
    Melanoma Res; 2012 Jun; 22(3):263-70. PubMed ID: 22516968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel immunotherapies as potential therapeutic partners for traditional or targeted agents: cytotoxic T-lymphocyte antigen-4 blockade in advanced melanoma.
    Agarwala SS
    Melanoma Res; 2010 Feb; 20(1):1-10. PubMed ID: 19952852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolving impact of long-term survival results on metastatic melanoma treatment.
    Michielin O; Atkins MB; Koon HB; Dummer R; Ascierto PA
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33037115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Melanoma immunotherapy: historical precedents, recent successes and future prospects.
    Raaijmakers MI; Rozati S; Goldinger SM; Widmer DS; Dummer R; Levesque MP
    Immunotherapy; 2013 Feb; 5(2):169-82. PubMed ID: 23413908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy of melanoma: efficacy and mode of action.
    Wieder T; Brenner E; Braumüller H; Röcken M
    J Dtsch Dermatol Ges; 2016 Jan; 14(1):28-37. PubMed ID: 26713633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Next generation of immunotherapy for melanoma.
    Kirkwood JM; Tarhini AA; Panelli MC; Moschos SJ; Zarour HM; Butterfield LH; Gogas HJ
    J Clin Oncol; 2008 Jul; 26(20):3445-55. PubMed ID: 18612161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Ctla-4 blockade: a new hope for the immunotherapy of malignant melanoma].
    Lotem M; Merims S; Frank S; Ospovat I; Peretz T
    Harefuah; 2012 Oct; 151(10):585-8, 604. PubMed ID: 23316667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on immunotherapy in melanoma.
    Green J; Ariyan C
    Surg Oncol Clin N Am; 2015 Apr; 24(2):337-46. PubMed ID: 25769716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy for advanced melanoma: fulfilling the promise.
    Gogas H; Polyzos A; Kirkwood J
    Cancer Treat Rev; 2013 Dec; 39(8):879-85. PubMed ID: 23725878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab.
    Eroglu Z; Kim DW; Wang X; Camacho LH; Chmielowski B; Seja E; Villanueva A; Ruchalski K; Glaspy JA; Kim KB; Hwu WJ; Ribas A
    Eur J Cancer; 2015 Nov; 51(17):2689-97. PubMed ID: 26364516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.